Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederpubmed.ncbi.nlm.nih.gov
Durva OR Treme OR Pembrolizumab OR nivolumab OR atezolizumab OR sasanlimab OR tarlatamab AND lung cancer AND 2025:2025[pdat] AND 2025:2025[pdat]
Get the latest updates from Durva OR Treme OR Pembrolizumab OR nivolumab OR atezolizumab OR sasanlimab OR tarlatamab AND lung cancer AND 2025:2025[pdat] AND 2025:2025[pdat] directly as they happen.
Follow now 166 followers
Latest posts
Last updated about 6 hours ago
PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: a French nationwide cohort study
about 15 hours ago
Lancet Reg Health Eur. 2025 Oct 9;59:101484. doi: 10.1016/j.lanepe.2025.101484. eCollection 2025 Dec.ABSTRACTBACKGROUND...
Brain Atrophy and Leukoencephalopathy Following Tarlatamab: Case Report
about 15 hours ago
Respirol Case Rep. 2025 Oct 22;13(10):e70383. doi: 10.1002/rcr2.70383. eCollection 2025 Oct.ABSTRACTWe describe...
A Multicenter, Retrospective, Real-World Study of Atezolizumab Plus Chemotherapy and Pembrolizumab Plus Chemotherapy for Older Patients With NSCLC
about 15 hours ago
JTO Clin Res Rep. 2025 Aug 21;6(11):100891. doi: 10.1016/j.jtocrr.2025.100891. eCollection 2025 Nov.ABSTRACTINTRODUCTION...
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; durvalumab, cemiplimab, zongertinib, and taletrectinib for lung cancer, pirtobrutinib and atezolizumab for lymphoma, durvalumab for bladder cancer, pa
3 days ago
Int J Clin Oncol. 2025 Oct 25. doi: 10.1007/s10147-025-02901-3. Online ahead of...
Metabolic phenotype and gender may predict treatment outcomes of atezolizumab in extensive-stage small cell lung cancer
4 days ago
Transl Lung Cancer Res. 2025 Sep 30;14(9):3836-3846. doi: 10.21037/tlcr-2025-300. Epub 2025 Sep...
Pseudoprogression of pleural effusion in lung cancer treated with immunotherapy: a case report
4 days ago
Transl Lung Cancer Res. 2025 Sep 30;14(9):4143-4148. doi: 10.21037/tlcr-2025-397. Epub 2025 Sep...
Combination of racotumomab immunotherapy with programmed death-1 blockade in a preclinical model of non-small cell lung cancer
4 days ago
Transl Lung Cancer Res. 2025 Sep 30;14(9):3607-3622. doi: 10.21037/tlcr-2025-230. Epub 2025 Sep...
Real-world insights into atezolizumab plus bevacizumab, carboplatin, and paclitaxel for advanced non-squamous non-small cell lung cancer
4 days ago
Transl Lung Cancer Res. 2025 Sep 30;14(9):3811-3823. doi: 10.21037/tlcr-2025-393. Epub 2025 Sep...
Real-world outcomes and association between immune-related adverse events and therapeutic efficacy of nivolumab plus ipilimumab in elderly patients (75 years) with advanced non-small cell lung cancer
4 days ago
Transl Lung Cancer Res. 2025 Sep 30;14(9):3861-3871. doi: 10.21037/tlcr-2025-640. Epub 2025 Sep...
The effect of tislelizumab on complete and pathological complete response in non-small cell lung cancer: a systematic review and meta-analysis
4 days ago
Front Oncol. 2025 Oct 8;15:1657282. doi: 10.3389/fonc.2025.1657282. eCollection 2025.ABSTRACTBACKGROUND: Immune checkpoint inhibitors...
Toxic epidermal necrolysis as a rare complication of pembrolizumab immunotherapy in the treatment of squamous cell lung cancer
5 days ago
Pol Arch Intern Med. 2025 Oct 23:17145. doi: 10.20452/pamw.17145. Online ahead of...
A Phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer
5 days ago
Cancer. 2025 Nov 1;131(21):e70141. doi: 10.1002/cncr.70141.ABSTRACTBACKGROUND: Treatment options for patients with advanced...